An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Electromed, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Electromed, Inc. (NYSE American: ELMD) announced that Kathleen Skarvan, President and CEO, and Michelle Wirtz, Interim CFO, will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022. They will also be available for one-on-one investor meetings on August 10, 2022. Electromed specializes in airway clearance technologies, including the SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. The company is based in New Prague, Minnesota, and was founded in 1992.
Positive
None.
Negative
None.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--
Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Kathleen Skarvan, President and Chief Executive Officer, and Michelle Wirtz, Interim Chief Financial Officer, are scheduled to participate in the Canaccord Genuity 42nd Annual Growth Conference on August 8-11, 2022. Management will be available for investor one-on-ones on Wednesday, August 10, 2022.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992. Further information about the Company can be found at www.smartvest.com.